SironRX Therapeutics is a Cleveland, OH-based biotechnology company developing novel regenerative therapies to accelerate dermal and bone healing. Its lead product, JVS100, is a clinically tested therapy that encodes Stromal cell-Derived Factor-1 (SDF-1), a molecule produced in response to tissue injury that activates natural repair processes, prevents cell death and recruits stem cells. The company develops therapies exclusively licensed from Juventas Therapeutics and Cleveland Clinic. SironRX plans to evaluate JVS100’s safety and efficacy in the treatment of post-surgical wounds as its first clinical indication. The company closed a $3.4M Series A and intends to use the funds to build its team and execute key clinical-stage milestones. SironRX is led by co-founder, President and CEO Rahul Aras, Ph.D., and Claiborne Rankin of North Coast Angel Fund serves as the company's board chairman. SironRX Therapeutics is developing JVS-100, a clinically tested biopharmaceutical that encodes Stromal cell-Derived Factor-1 (SDF-1) as a topical therapy to promote wound repair and prevent scarring in post-surgical wounds. The company plans to use recent funding to begin a Phase II clinical trial of JVS-100. Preclinical studies cited broader dermal applications for the candidate, including treatment of chronic ulcers and burns. SironRX is a spinoff of Juventas Therapeutics; Juventas licensed the drug’s intellectual property from Cleveland Clinic in 2007. The company is based in Cleveland, OH, and its CSO is Marc Penn, M.D., Ph.D., Director of the Skirball Cardiovascular Cell Therapy Laboratory at Cleveland Clinic. Operationally it has received a $500,000 investment from JumpStart Ventures and Cleveland Clinic as part of a larger fundraising round.

Total raised

$4M

Funding rounds

2

Latest round

Series A

Latest activity

Aug 2011